Head-to-head evidence
BCD-281 vs Ocrelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
BCD-281
Developed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07321093 (registry estimate)
Ocrelizumab
Marketed by Roche
NCT00676715 · Phase 2 · completed
Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result.
Next expected readout: October 2026 · NCT03523858 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-281's landscape · Ocrelizumab's landscape